Article
Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.
Breast cancer research and treatment - 1 Oct 2017
Nitz Ulrike, Gluz Oleg, Christgen Matthias, Kates Ronald E, Clemens Michael, Malter Wolfram, Nuding Benno, Aktas Bahriye, Kuemmel Sherko, Reimer Toralf, Stefek Andrea, Lorenz-Salehi Fatemeh, Krabisch Petra, Just Marianne, Augustin Doris, Liedtke Cornelia, Chao Calvin, Shak Steven, Wuerstlein Rachel, Kreipe Hans H, Harbeck Nadia
Abstract excerpt
BACKGROUND: The prospective phase 3 PlanB trial used the Oncotype DX® Recurrence Score® (RS) to define a genomically low-risk subset of clinically high-risk pN0-1 early breast cancer (EBC) patients for treatment with adjuvant endocrine therapy (ET) alone. Here, we report five-year data evaluating the prognostic value of RS, Ki-67, and other traditional clinicopathological parameters. METHODS: A central tumour...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.